If ohm20's name was on the BOD, I would take out
Post# of 148111
I believe that if the company pursued more combo-therapies with lesser ambitions it would better serve the company just getting the molecule in play. Bayer aspirin is cheap by comparison but what a gold mine. Some lesser indications might be the answer, but not on our own dime. We need someone to keep the molecule relevant & the balance sheet in order. Then maybe bigger & better.How many multivitamins are turning profits? The whole 3 digits is a thing of the past- at least for now& it is past time to deal with now. And that should be a great deal if pursued & marketed correctly ($10- $20PPS IMHO)